The primary DLBCL cells we used in all our assays, from a single donor, expressed FcγRIIB (Figure 8D), a receptor known to bind the Fc portion of rituximab at the lymphoma cell surface resulting in its internalization and/or trogocytosis (30). Here, FCGR2B is linked to diffuse large B-cell lymphoma.